This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07400679 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Pfizer |
| Enrollment | 48 participants |
| Design | Interventional, Randomized, Parallel, Masking: None |
| Conditions | Overweight; Obesity; Healthy |
| Interventions | PF-08653944 |
| Start | Feb 4, 2026 |
| Primary completion | Jul 2, 2026 |
| Study completion | Jul 8, 2026 |
| Results posted | Not yet |
| Registry last updated | Aug 17, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study is being done to learn how the study medicine affects the body and how safe it is for people who take it. The researchers will look at a number of health tests, including blood tests such as calcitonin, amylase, and lipase, because similar medicines have sometimes caused changes in these tests.
This study is seeking participants who are:
* Adults who are obese or overweight with weight-related health conditions, and
* Meet health and other checks assessed by the study doctor.
The study team will give a single dose of the study treatment at the clinic to the participants. At each study visit, blood samples will be collected, vital signs will be checked, and the study team will ask about any reactions or health changes. Vital signs are basic measurements that show how well the body is working. They help the study team quickly understand a participant's overall health. These usually include body temperature, heart rate, breathing rate, and blood pressure.
The study involves multiple clinic visits at a study site over the length of the study. The information collected will help researchers understand how the study medicine works and whether it is safe.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of PF-08653944 | Up to 85 days |
| PK: Maximum Observed Concentration (Cmax) of PF-08653944 | Up to 85 days |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
More trials of Berobenatide
- A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the (Phase 1 NCT07508241)
- A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver (Phase 1 NCT07519135)
More from Pfizer
- VESPER-OSA 2: sleep apnea without airway pressure therapy (Phase 3 NCT07881757)
- Once-monthly berobenatide in Chinese adults (Phase 3) (Phase 3 NCT07874633)
- VESPER-JW: once-weekly berobenatide in Japan (Phase 3 NCT07794761)
- VESPER-SWITCH: monthly berobenatide for weight maintenance (Phase 3 NCT07845500)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.